GRI Bio, Inc. — Director's Dealing 2022

Mar 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vallon Pharmaceuticals, Inc. (VLON)
CIK: 0001824293
Period of Report: 2022-02-15

Reporting Person: Kelly Leanne M. (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-15	Stock Option (Right to Buy)	$5.63	A	50000	Acquired	2032-02-15	Common Stock (50000.0)	Direct

Footnotes

F1: Reported late due to administrative error.

F2: Vests as to 25% of the underlying shares of common stock on the first annual anniversary of the date of grant, then in 12 equal quarterly installments such that the stock option is fully vested on the fourth annual anniversary of the date of grant.